Tagged with Oncology

Morocco Morocco has made admirable progress in building a national oncology network in recent years, but the country’s cancer patients still face significant challenges in terms of accessing the latest therapies. Here, the Morocco heads of companies with global portfolios of innovative cancer treatments discuss the current situation and how they…

China PharmaBoardroom caught up with Alphamab Oncology’s founder, chairman and CEO Dr Xu Ting again 16 months after our last interview to hear about their successful HKEX IPO in December 2019, his commercial expectations for their flagship PD-1/PD-L1 product, and the impact of COVID-19 on their operations.   The core business…

Belgium Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and how the importance of the Society’s network of international partnerships.   We need to have everyone on board, in order…

Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…

Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…

Morocco Pierre Behnam, general manager of Pierre Fabre in Morocco, breaks down the strong and long-standing footprint of the group in the country in the medical and dermo-cosmetic fields. On the medical side, he talks about the amazing progress Morocco has made in the prevention and treatment of cancer, and his…

Belgium PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies.   As a multicultural company, we believe in the future growth of Belgium’s innovative biotechnology sector. It is absolutely a country which should be…

Romania Daniel Bran, GM of Accord Romania reveals that finding the right talent has been one of the most challenging and rewarding milestones in building the affiliate from the ground up. He shares his insights on what is driving Accord’s growth and how launching nearly 20 new products a year has…

Romania Cătălin Radu of Bristol Myers Squibb (BMS) Romania explains how the Celgene acquisition is allowing the company to provide their expertise on a larger scale. He reveals how BMS has become Romanian market leader in immuno-oncology by launching new indications and therapy lines for its products in the country. He…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Belgium There are over 3.5 million diagnoses and 1.3 million deaths from cancer in the EU each year and cancer is set to become the region’s leading cause of death without a reversal of current trends. Against this backdrop, the European Commission is launching the ‘Europe’s Beating Cancer Plan’ to reduce…